Supplementary Figure S1: Agonist-binding to live cell M 2 receptors is independent of the receptor's preferred G protein. Equilibrium binding of acetylcholine (a), iperoxo (b), iper-6-phth (c), iper-6-naph (d), iper-8-naph (e) and iper-6 and iper-8-phth (f) competing against [³H]NMS was measured in either untreated live CHO-hM 2 cells (filled symbols) or in PTX-pretreated (100 ng/ml, 16-24 h) CHO-hM 2 cells, when indicated (open symbols). Data are means ± s.e.m. from at least three independent experiments conducted in triplicates. Curve fitting was based on either a four-parameter logistic function or, if maximum [³H]NMS-displacement was not complete, the allosteric ternary complex model (for details see 24,29 ).
SUPPLEMENTARY FIGURES

Supplementary Figure S1
Iper-6-phth 6.11 ± 0.06 (-1.30 ± 0.04) 6.00 ± 0.07 (-1.38 ± 0.03)
Iper-6-naph
7.07 ± 0.08 (-0.35 ± 0.01) 6.82 ± 0.22 (-0.39 ± 0.01)
Iper-8-phth
6.79 ± 0.21 N.D.
Iper-8-naph
7.79 ± 0.06 (-0.89 ± 0.04) 7.79 ± 0.02 (-0.73 ± 0.02) Supplementary Table S1 : Affinity and cooperativity of muscarinic agonists in equilibrium radioligand binding assays. Data points derived from equilibrium binding assays of indicated muscarinic agonists competing against [³H]NMS in control or PTXpretreated CHO-hM 2 cells, respectively, were subjected to curve fitting based either on a 4parameter logistic function or on the allosteric ternary complex model (iper-6-phth, iper-6naph and iper-8-naph). Values are means ± s.e.m. of at least three independent experiments conducted in triplicate. pK, minus log value of the apparent equilibrium dissociation constant; pα, minus log value of the cooperativity factor. N.D. not determined.
Ligand
Gi protein signaling Gs protein signaling Supplementary Table S2 : Efficacies of muscarinic agonists in DMR assays. Pilocarpi ne 65 ± 2 *** 8 ± 3 10 ± 3 *** 1 ± 1
McN-A-343
24 ± 4 *** 1 ± 1 22 ± 4 *** 0 ± 1 Supplementary Table S6 : Efficacies of muscarinic agonists at hM 2 WT and hM 2 W422A cells in DMR assays. Maximum positive or negative peak DMR responses of indicated muscarinic agonists in CHO-hM 2 WT and CHO-hM 2 W422A cells were normalized on the peak Figure S7 .
Synthesis of 6-Bromo-N,N,N-trimethylhexane-1-ammonium Bromide 7
50 mmol trimethylammonium hydrochloride and 80 mmol 1,6-dibromohexane were dissolved in ethanol. A solution of 65 mmol potassium hydroxide was added slowly dropwise and the mixture was left for three days at room temperature. The white precipitate was filtered off and the filtrate was poured into ice-cold diethyl ether. The mixture was cooled to 4 °C and the white precipitate extracted with acetone with a Soxhlet extractor. The extract was poured into diethyl ether and the precipitate filtered off and dried in vacuo to yield 7 as a white solid in 78% yield (lit. 57 95 %).
Mp 112 °C (lit. 57 106-108 °C). The NMR spectroscopic features and the purity requirements of these known compounds matched those found in the literature.
Synthesis of Diammonium Compounds 2, 4, and 6
4-((4,5-Dihydroisoxazol-3-yl)oxy)-N,N-dimethylbut-2-yn-1-amine 8 (1 mmol) and monoquaternary bromide 7 (or 10a or 10b) (1 mmol) were dissolved in acetonitrile (30 ml) and refluxed for 3 days in the presence of a catalytic amount of KI/K 2 CO 3 . After the reaction was completed (TLC monitoring, eluent: 0.2 M aqueous KNO 3 /CH 3 OH 2:3), about one half of the solvent was evaporated and the obtained colorless solid was collected by filtration and recrystallized. The precipitate was filtered, washed with diethylether, and dried in vacuo to give the desired salt in 35% (2), 71% (4), and 58% (6) yield. [4-(4,5-Dihydroisoxazol-3-yloxy)but-2-ynyl]-N,N,N',N',N ' -pentamethyl-hexane-1 N-[4-(4,5-Dihydroisoxazol-3-yloxy)but-2-ynyl]-N'-[3-(1,3-dioxoisoindol-2-yl)-propyl]-N,N,N',N'-tetramethyl-octane-1,8- N-[4-(4,5-Dihydroisoxazol-3-yloxy)but-2-ynyl]-N'-[3-(1,3-dioxo-benzo[de]isoquinolin-2-yl) .6, 25.8, 28.2 ( + NCH 2 CH 2 × 2), ( + N(CH 2 ) 2 CH 2 × 2) and ( + N(CH 2 ) 3 CH 2 × 2), respectively; 26.7 (C(CH 3 ) 2 ); 33.1 (C-4 2-Isox ); 39.5 (C(CH 3 ) 2 ); 48.2 (N Naphth CH 2 ); 50.6 and 51.0 ( + N(CH 3 ) 2 ); 53.1 ( + NCH 2 C≡); 57.6 (≡CCH 2 O); 64.2 (CH 2 + NCH 2 C≡); 68.6 (CH 2 + NCH 2 C(CH 3 ) 2 ); 
N-
Materials and reagents
Tissue culture media and assay reagents were purchased from Sigma-Aldrich (Taufkirchen, between residues L91 and K92, and GFP10-Gγ 2 were a kind gift from Michel Bouvier (Université de Montréal, Montreal). To create a hM 2 receptor FRET-sensor the hM 2 receptor was modified by introducing the above-mentioned FLAG-and hemagglutinin tags at the N-terminus as described previously 41 . The receptor's C terminus was directly fused to eCFP by deleting the STOP codon and the initiating methionine of eCFP. In contrast to the previously published hM 2 receptor FRET-sensor 41 the third intracellular loop (IL3) had not been truncated, rather the FlAsH binding motif CCPGCC was introduced into the IL3 beneath the transmembrane domain 5 (TM5) between the amino acid residues Asp229 and Pro230 and sequence identity was verified by the sequencing technique provided by New England Biolabs (Ipswich, MA).
Transient transfection methods
To effectively deliver cDNA for BRET assays into HEK293 and COS-7 cells an electroporation method was used as described previously 61 . To perform β-arrestin2 recruitment, five million HEK293 cells stably expressing GFP2-β-arr2 were electroporated with 2 µg hM 2 receptor-Rluc, 4 µg G protein-coupled receptor kinase 2 (GRK2) and 4 µg empty vector. For measurement of G protein subunit rearrangements, five million COS-7 cells were transfected by electroporation with 3 µg hM 2 receptor, 2 µg Gα i1 -91Rluc, 1 µg Gβ 1 , 0.5 µg GFP10-Gγ 2 and 2.5 µg empty vector. CHO-K1 cells used in DMR measurements were transfected with cDNA encoding either
